This article refers to:
Article title: Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer
Authors: Ricardo E Perez, Sarah Calhoun, Daeun Shim, Victor V. Levenson, Lei Duan, and Carl G. Maki
Journal: CANCER BIOLOGY & THERAPY
Bibliometrics: Volume 21, Number 11, pages 1033–1040
DOI: https://doi.org/10.1080/15384047.2020.1824989
It has been noted by the authors that the DOD grant support number listed in the original publication was incorrect. The grants that supported this work were National Cancer Institute grant [R01CA200232-05] and Department of Defense Grant [W81XWH-16-1-0025] both to C.G.M.
Additional information
Funding
This work was partially funded by the U.S. Environmental Protection